Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 ISIN · KYG2606C1006 HKEX Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2024-04-26 Annual Report
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
2023 Annual Report
Annual Report Classification · 100% confidence The document is titled 'Cutia Therapeutics Annual Report 2023' and contains detailed sections typical of a full annual report, including Corporate Information, Chairman's Statement, Highlights, Corporate Profile, Management Discussion and Analysis, Financial Summary, Corporate Governance Report, Directors' Report, Directors and Senior Management, Independent Auditor's Report, and detailed financial statements such as Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position, Changes in Equity, Cash Flows, and Notes to Financial Information. The document covers the full fiscal year ended 31 December 2023 and includes comprehensive financial data, business review, operational highlights, and governance information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 31 March 2024. It details movements in authorized and issued shares, share options, and confirms compliance with listing rules. It is a regulatory submission related to share capital and securities movements, not a financial report, earnings release, or management discussion. It does not announce voting results, board changes, or capital raising events. The document is a regulatory filing reporting share capital movements and confirmations to the exchange, fitting the definition of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory filing.
2024-04-05 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023' and contains detailed financial highlights, business review, management discussion and analysis, and operational updates for the full fiscal year 2023. It includes audited consolidated annual results, revenue figures, cash and equivalents, and extensive discussion of business segments and pipeline products. The length is substantial (15,000 characters), and the content is comprehensive, not merely an announcement or summary. This matches the characteristics of an Annual Report (10-K) rather than a short Earnings Release or a Report Publication Announcement. Therefore, the document is best classified as an Annual Report (10-K). FY 2023
2024-03-27 English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the acceptance of an investigational new drug application by a regulatory body (Center for Drug Evaluation of the National Medical Products Administration). It is a short announcement (3024 characters) informing shareholders and investors about a business development related to drug approval. There are no financial statements, no detailed financial data, no meeting materials, no voting results, no management discussion, no earnings data, and no regulatory certifications. The document is clearly an announcement of a business update rather than a report or detailed filing. It fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-03-26 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN FTSE GLOBAL EQUITY INDEX SERIES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the company's inclusion in the FTSE Global Equity Index Series. It is a short announcement (2338 characters) that informs the market about an index inclusion event, which is a capital market recognition but does not contain financial statements, detailed financial data, or management discussion. It is not a report or financial filing but a market update. The document does not announce voting results, changes in management, or legal proceedings. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category that does not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-03-18 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from the board of directors of Cutia Therapeutics regarding the scheduling of a board meeting to consider and approve the annual results for the year ended 31 December 2023, and to consider the recommendation of a final dividend. The document is short (1506 characters) and does not contain any financial data or the actual annual report. It is a notice about the timing of the board meeting and the upcoming publication of results, not the results themselves. Therefore, it fits the category of a Report Publication Announcement (RPA), which is used for announcements about the timing or release of company reports rather than the reports themselves.
2024-03-14 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.